Cost-effectiveness and budget impact of PFO closure: Cardioform vs Amplatzer and medical therapy for secondary stroke prevention in Australia
Cardioform appears more cost-effective in the prevention of secondary PFO-associated strokes, supporting its adoption in clinical practice.
Authors
- Ross Sharpe
- Timon Louwsma (ORCID: https://orcid.org/0009-0005-3368-8774)
- G. Starmer
- Andrew Wong (ORCID: https://orcid.org/0009-0009-3647-8325)
- Bianca Camuglia
- David Fox
- Hassan ElMarkaby
Institutions
- W. L. Gore & Associates (Germany) (DE)
- Royal Brisbane and Women's Hospital (AU)
- Cairns Hospital (AU)
- Coastal Orthopedics (US)
- Academic Software (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1080/13696998.2026.2622856
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00